诱导性多功能干细胞製造市场规模、份额、成长分析、按细胞类型、按工艺、按工作流程、按产品类型、按应用、按最终用户 - 行业预测，2024-2031

诱导性多功能干细胞製造的全球市场规模在2022年估值为12.2亿美元，从2023年的13.5亿美元增长到2031年的30亿美元，并预计在预测期内增长（2024-预计将以2031 年复合年增长率为10.5%）。

全球诱导性多功能干细胞(iPSC) 製造市场在再生医学和细胞治疗领域正在经历快速成长和创新。源自成体细胞并重新编程为多功能状态的 iPSC 为个人化治疗选择和疾病建模提供了巨大潜力。这种增长是由于人们越来越认识到 iPSC 的多种应用（从药物发现到各种疾病的治疗）。研究人员和生物技术公司正在努力开发高效的 iPSC 生产方法，在学术界、工业界和医疗保健部门之间的合作的推动下，确保可扩展性和成本效益。然而，严格的监管标准和道德考量在影响 iPSC 的生产方式方面发挥关键作用，凸显了标准化方案和安全措施的重要性。随着全球医疗保健格局的发展，iPSC 製造市场预计将进一步扩大，为突破性的医学进步和治疗性介入铺平道路。

目录

介绍

• 这项研究的目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场危机与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 专利分析
• 市场生态系统
• 价值链分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 竞争程度

按细胞类型分類的诱导性多功能干细胞製造市场

• 市场概况
• 肝细胞
• 纤维母细胞
• 角质形成细胞
• 神经元
• 其他的

依製程分類的诱导性多功能干细胞製造市场

• 市场概况
• 手动 iPSC 製造流程
• 自动化 iPSC 製造流程

依工作流程诱导性多功能干细胞製造市场

• 市场概况
• 重编程、细胞培养
• 细胞表征/分析
• 工程
• 其他的

按产品分類的诱导性多功能干细胞製造市场

• 市场概况
• 设备/装置
• 自动化平台
• 耗材和套件
  • 媒体
  • 套件
  • 其他的
• 服务

按应用分類的诱导诱导性多功能干细胞製造市场

• 市场概况
• 医药开发
• 再生医学
• 毒性试验
• 人体组织工程
• 其他的

最终用户诱导性多功能干细胞製造市场

• 市场概况
• 研究/学术机构
• 生物技术和製药公司
• 医院/诊所

按地区分類的市场规模

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Axl Bioscience Ltd.（UK）
• Cynata Therapeutics Limited（UK）
• Evotec SE（Germany）
• Fate Therapeutics, Inc.（US）
• FUJIFILM Cellular Dynamics, Inc.（US）
• Ncardia（Belgium）
• Pluricell Biotech（Spain）
• REPROCELL USA, Inc.（US）
• Sumitomo Dainippon Pharma Co., Ltd.（Japan）
• Takara Bio, Inc.（Japan）
• Thermo Fisher Scientific, Inc.（US）
• ViaCyte, Inc.（US）

Global Induced Pluripotent Stem Cells Production Market size was valued at USD 1.22 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3 billion by 2031, growing at a CAGR of 10.5% during the forecast period (2024-2031).

The global market for induced pluripotent stem cell (iPSC) manufacturing is experiencing rapid growth and innovation within the field of regenerative medicine and cellular therapy. Derived from adult cells and reprogrammed to a pluripotent state, iPSCs offer significant potential for personalized treatment options and disease modeling. This growth is fueled by increasing awareness of iPSCs' diverse applications, spanning from drug discovery to treating various medical conditions. Efforts are underway by researchers and biotech firms to develop efficient iPSC production methods that ensure scalability and cost-effectiveness, facilitated by collaborations across academia, industry, and healthcare sectors. However, stringent regulatory standards and ethical considerations play a crucial role in shaping iPSC manufacturing practices, emphasizing the importance of standardized protocols and safety measures. As the global healthcare landscape evolves, the iPSC manufacturing market is poised for further expansion, promising avenues for groundbreaking medical advances and therapeutic interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Induced Pluripotent Stem Cells Production Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Induced Pluripotent Stem Cells Production Market Segmental Analysis

The induced pluripotent stem cells production market is segmented on the basis of cell type, process, workflow, product, application, end-use and region. Based on cell type, the market is segmented into Hepatocytes, Fibroblasts, Keratinocytes, Neurons and Others. Based on the process, the market is segmented into Manual iPSC Production Process and Automated iPSC Production Process. Based on workflow, the market is segmented into Reprogramming, Cell Culture, Cell Characterization/Analysis, Engineering, and Others. Based on product, the market is segmented into Instruments/ Devices, Automated Platforms, Consumables & Kits (Media, Kits, Others), and Services. Based on application, the market is segmented into Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, and Others. Based on end-user, the market is segmented into Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Drivers of the Global Induced Pluripotent Stem Cells Production Market

A significant driving force in the global pluripotent stem cell (iPSC) manufacturing market is the ongoing advancements in regenerative medicine. iPSCs offer substantial potential for tailoring effective therapies across various medical conditions, prompting substantial investments in research and development. This advancement propels market expansion through broadening the range of iPSC applications, offering novel treatment avenues, and drawing investments from pharmaceutical firms and healthcare institutions.

Restraints in the Global Induced Pluripotent Stem Cells Production Market

One significant obstacle in the global iPSC production market stems from ethical and regulatory hurdles. Issues surrounding the use of human-derived materials and the potential for iPSC technology misuse have led to the implementation of strict regulations in certain regions. These challenges may impede research endeavors, increase compliance costs, and generate market uncertainty, thereby affecting the pace of iPSC adoption and commercialization.

Market Trends of the Global Induced Pluripotent Stem Cells Production Market

One significant trend in the global induced pluripotent stem cell (iPSC) manufacturing market is the growing utilization of iPSCs for disease modeling, with researchers and pharmaceutical companies employing iPSC technology to generate disease-specific cell lines. This approach enables more precise and personalized modeling of a range of diseases, including genetic disorders, neurodegenerative conditions, and cardiovascular ailments. Such advancements facilitate drug discovery and development while also fostering the development of targeted and efficient therapeutic strategies, thereby influencing the trajectory of precision medicine in the future.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Patent Analysis
• Ecosystem of the Market
• Value Chain Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Induced Pluripotent Stem Cells Production Market by Cell Type

• Market Overview
• Hepatocytes
• Fibroblasts
• Keratinocytes
• Neurons
• Others

Induced Pluripotent Stem Cells Production Market by Process

• Market Overview
• Manual iPSC Production Process
• Automated iPSC Production Process

Induced Pluripotent Stem Cells Production Market by Workflow

• Market Overview
• Reprogramming, Cell Culture
• Cell Characterization/Analysis
• Engineering
• Others

Induced Pluripotent Stem Cells Production Market by Product

• Market Overview
• Instruments/ Devices
• Automated Platforms
• Consumables & Kits
  • Media
  • Kits
  • Others
• Services

Induced Pluripotent Stem Cells Production Market by Application

• Market Overview
• Drug Development
• Regenerative Medicine
• Toxicity Testing
• Tissue Engineering
• Others

Induced Pluripotent Stem Cells Production Market by End-user

• Market Overview
• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics

Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Axl Bioscience Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics Limited (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Cellular Dynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ncardia (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluricell Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REPROCELL USA, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViaCyte, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments